Tempus AI obtained FDA approval expanding its xT CDx comprehensive genomic profiling assay to a tumor-only use case when matched normal tissue is not viable. Tempus said the 648-gene tissue assay can also determine microsatellite instability status from tumor DNA alone and is positioned as a companion diagnostic for specific colorectal cancer targeted-therapy scenarios. Delfi Diagnostics secured New York State approval to offer its FirstLook Lung blood-based liquid biopsy LDT for lung cancer screening in all 50 states, clearing a state review gate while pursuing eventual FDA authorization. The company cited evidence that the blood test can nearly triple screening uptake in a near-3,000-patient study. Both moves expand the practical deployment of molecular tests into real-world clinical workflows—either by reducing sample requirements or by improving screening reach.